Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	Phase III study of T-3262G15% in the pediatric patients with mycoplasma pneumonia
	Primary sponsor	Toyama Chemical Co., Ltd
	Study Type	interventional (treatment)
	Summary	The objectives of this study are to evaluate the efficacy and safety of T-3262G15% in the pediatric patients with mycoplasma pneumonia compared with clarithromycin.
Details of study	Interventional drug name	T-3262G15% (Tosufloxacin Tosilate Hydrate)
	Target illness	Mycoplasma pneumonia
	Classification name (code) of the investigational drug	624
	Administration route	Oral
	Control drug name	Clarithromycin
	Classification name (code) of the investigational drug	614
	Administration route	Oral
	Objectives of the study	Treatment
	Study phase	Phase 3
	Study design	A multi-center, randomized, open-label, comparative study
	Inclusion Criteria	(1) Age: between 1 and 15 years old (2) Sex: male or female (3) Outpatient or inpatient (4) Presence of symptom/findings of mycoplasma pneumonia (5) Others
	Exclusion Criteria	(1) Medical history of allergy to any quinolone or macrolide antibacterial agents (2) Pregnant females, being possibly pregnant, or lactating females (3) Others
	Outcome	Efficacy and safety
	Study status	Complete
	Duration of the study	-
	Region	Japan
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Data Science and Administration Department
	Contact	Form for Inquiry https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn